41 related articles for article (PubMed ID: 37231874)
1. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
2. Acute Myeloid Leukemia following Radioactive Iodine Therapy for Metastatic Follicular Carcinoma of the Thyroid.
Bishnoi K; Emerson R; Parida GK; Acharya P; Padhi S; Agrawal K
Indian J Nucl Med; 2023; 38(1):56-58. PubMed ID: 37180180
[TBL] [Abstract][Full Text] [Related]
3. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
4. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
Nguyen NC; Anigati EM; Desai NB; Öz OK
Semin Nucl Med; 2024 May; ():. PubMed ID: 38772827
[TBL] [Abstract][Full Text] [Related]
5. Curcumin induces mitophagy by promoting mitochondrial succinate dehydrogenase activity and sensitizes human papillary thyroid carcinoma BCPAP cells to radioiodine treatment.
Zhang L; Qiu L; Xu S; Cheng X; Wu J; Wang Y; Gao W; Bao J; Yu H
Toxicol In Vitro; 2023 Dec; 93():105669. PubMed ID: 37634662
[TBL] [Abstract][Full Text] [Related]
6. Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy.
Mishra A; Singh V; Khandelwal Y; Smitha AM; Kavali DJP; Barai S
Indian J Nucl Med; 2023; 38(3):264-269. PubMed ID: 38046960
[TBL] [Abstract][Full Text] [Related]
7. Second Primary Malignancy After Radioiodine Therapy in Thyroid Cancer Patient: A Nationwide Study.
Hong CM; Son J; Hyun MK; Lee JW; Lee J
Nucl Med Mol Imaging; 2023 Dec; 57(6):275-286. PubMed ID: 37982105
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.
Hong CM; Ahn BC
Nucl Med Mol Imaging; 2018 Aug; 52(4):247-253. PubMed ID: 30100937
[TBL] [Abstract][Full Text] [Related]
9. Eye-Related Adverse Events After I-131 Radioiodine Therapy: A Systematic Review of the Current Literature.
Rahmanipour E; Askari E; Ghorbani M; Mirzaei M; Rahimi B; Daskareh M; Mirshahvalad SA
Endocr Pract; 2024 Apr; ():. PubMed ID: 38697307
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
11. Chronic myeloid leukemia in a woman with papillary carcinoma of the thyroid treated with radioactive iodine.
Alfiar F; Amato D; Lipton JH
Leuk Lymphoma; 1997 Oct; 27(3-4):365-7. PubMed ID: 9402335
[TBL] [Abstract][Full Text] [Related]
12. Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.
Ali Hailan YM; Al-Dubai HN; Yassin MA
Oncology; 2023; 101(6):362-368. PubMed ID: 37231874
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature.
Shimon I; Kneller A; Olchovsky D
Clin Endocrinol (Oxf); 1995 Nov; 43(5):651-4. PubMed ID: 8548952
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma.
Wang KL; Lin LY; Chen PM; Lin HD
J Chin Med Assoc; 2005 May; 68(5):230-3. PubMed ID: 15909729
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia in a man with papillary carcinoma of the thyroid treated with radioactive iodine.
Pavithran K; Doval DC
Am J Clin Oncol; 2005 Apr; 28(2):216. PubMed ID: 15803020
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
